Key result
Acute administration of rosiglitazone before ischemia/reperfusion increased cardiac injury compared to control hearts, and TZDs caused dose-dependent increases in mitochondrial oxidation.
Why the study?
The effect of anti-diabetic thiazolidinediones on contributing to heart failure and cardiac ischemia/reperfusion injury is controversial.
Do thiazolidinediones increase ischemia/reperfusion injury and alter mitochondrial redox state in rat isolated hearts?
Do thiazolidinediones increase ischemia/reperfusion injury and alter mitochondrial redox state in rat isolated hearts?
Thiazolidinediones increase myocardial ischemia/reperfusion injury and cause mitochondrial uncoupling via a PPARγ-independent mechanism in a rat model.
Rosiglitazone may increase I/R injury in isolated hearts; leaves open clinical relevance of TZD mitochondrial effects.
The effect of anti-diabetic thiazolidinediones (TZDs) on contributing to heart failure and cardiac ischemia/reperfusion (IR) injury is controversial. In this study we investigated the effect of select TZDs on myocardial and mitochondrial function in Brown Norway rat isolated hearts. In a first set of experiments, the TZD rosiglitazone was given acutely before global myocardial IR, and pre- and post-IR function and infarct size were assessed. In a second set of experiments, different concentrations of rosiglitazone and pioglitazone were administered in the presence or absence of the specific PPARγ antagonist GW9662, and their effects on the mitochondrial redox state were measured by online NADH and FAD autofluorescence. The administration of rosiglitazone did not significantly affect myocardial function except for transiently increasing coronary flow, but it increased IR injury compared to the control hearts. Both TZDs resulted in dose-dependent, reversible increases in mitochondrial oxidation which was not attenuated by GW9662. Taken together, these data suggest that TZDs cause excessive mitochondrial uncoupling by a PPARγ-independent mechanism. Acute rosiglitazone administration before IR was associated with enhanced cardiac injury. If translated clinically, susceptible patients on PPARγ agonists may experience enhanced myocardial IR injury by mitochondrial dysfunction.
No takes yet. Share an insight, caveat, or question.
Riess et al. (2020) studied Myocardial ischemia/reperfusion injury. Thiazolidinediones (rosiglitazone and pioglitazone) vs. Control hearts was evaluated on Myocardial function, infarct size, and mitochondrial redox state. Acute administration of rosiglitazone before ischemia/reperfusion increased cardiac injury compared to control hearts, and TZDs caused dose-dependent increases in mitochondrial oxidation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: